{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:43:30Z","timestamp":1788864210968,"version":"build-2803163510"},"reference-count":27,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100018747","name":"SkylineDx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018747","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Over the years, numerous prognostic markers for multiple myeloma (MM) risk classification have been identified; however, their variability can lead to inconsistent clinical interpretations. Gene expression profiling (GEP) signatures, such as SKY92, offer a more accurate method for patient stratification. The PRospective Observational Multiple Myeloma Impact Study (NCT02911571) aimed to validate SKY92's prognostic performance using real\u2010world data and assess its impact on risk classification and treatment decisions compared to conventional markers. In a study of 251 newly diagnosed MM patients, physicians completed questionnaires to capture risk classification, hypothetical treatment plans and their confidence in those plans before and after unblinding SKY92 results. Poor concordance was observed between initial clinical risk assessment (iCRA) and SKY92 results (high risk: 51% iCRA vs. 28% SKY92, Cohen's\n                    <jats:italic>\u03ba<\/jats:italic>\n                    \u2009=\u20090.21). SKY92 showed superior performance in identifying high\u2010risk patients, leading to better predictions of progression\u2010free survival and overall survival (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009\u2264\u20090.0001) than traditional risk markers. Unblinding SKY92 results led to hypothetical treatment revisions for 50% of patients (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) and increased physicians' confidence in treatment decisions for 40% of cases. These findings support SKY92's prognostic value in identifying high\u2010risk MM patients, outperforming traditional risk markers and demonstrating the potential added value of its integration into clinical practice for more personalized risk assessment.\n                  <\/jats:p>","DOI":"10.1111\/bjh.20050","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T03:39:03Z","timestamp":1747971543000},"page":"1642-1653","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real\u2010world data"],"prefix":"10.1111","volume":"206","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0693-4202","authenticated-orcid":false,"given":"Noa","family":"Biran","sequence":"first","affiliation":[{"name":"Myeloma Division Hackensack University Medical Center  Hackensack New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4377-9742","authenticated-orcid":false,"given":"Binod","family":"Dhakal","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine Medical College of Wisconsin  Milwaukee Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Niesvizky","sequence":"additional","affiliation":[{"name":"Division of Hematology &amp; Medical Oncology Weill Cornell Medicine\/New York Presbyterian Hospital  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Columbia University Medical Center  New\u00a0York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5482-7543","authenticated-orcid":false,"given":"Divaya","family":"Bhutani","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Columbia University Medical Center  New\u00a0York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"McKay","sequence":"additional","affiliation":[{"name":"Atrium Health Wake Forest Baptist Medical Center  Winston\u2010Salem North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Vesole","sequence":"additional","affiliation":[{"name":"Myeloma Division Hackensack University Medical Center  Hackensack New Jersey USA"},{"name":"Lombardi Comprehensive Cancer Center Medstar Georgetown Medical Center  Washington District of Columbia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4165-6869","authenticated-orcid":false,"given":"Ajay","family":"Nooka","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute, School of Medicine Emory University  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2702-8225","authenticated-orcid":false,"given":"Barry","family":"Paul","sequence":"additional","affiliation":[{"name":"Department of Hematologic Oncology &amp; Blood Disorders, Levine Cancer Institute Atrium Health\/Wake Forest Baptist  Charlotte North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran N.","family":"Hari","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine Medical College of Wisconsin  Milwaukee Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7742-2215","authenticated-orcid":false,"given":"Silvia","family":"D'Ambrosi","sequence":"additional","affiliation":[{"name":"SkylineDx  Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowan","family":"Kuiper","sequence":"additional","affiliation":[{"name":"SkylineDx  Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"van Vliet","sequence":"additional","affiliation":[{"name":"SkylineDx  Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Siegel","sequence":"additional","affiliation":[{"name":"Myeloma Division Hackensack University Medical Center  Hackensack New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[{"name":"Department of Medicine Memorial Sloan Kettering Cancer Center  New York New\u00a0York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[{"name":"Myeloma Center, Winthrop P. Rockefeller Cancer Institute University of Arkansas for Medical Sciences  Little Rock Arkansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00135-5"},{"key":"e_1_2_13_3_1","first-page":"3","article-title":"Epidemiology, staging, and management of multiple myeloma","volume":"9","author":"Padala SA","year":"2021","journal-title":"Med Sci"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00165-X"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-358812"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00665-7"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"e_1_2_13_8_1","unstructured":"mSMART.Mayo stratification for myeloma and risk\u2010adapted therapy.2024."},{"key":"e_1_2_13_9_1","volume-title":"Clinical practice guideline multiple myeloma","author":"Quach H","year":"2022"},{"key":"e_1_2_13_10_1","unstructured":"KumarSK CallanderNS AdekolaK AndersonLD BaljevicM BazR et\u00a0al.NCCN guidelines Version 1.2025 multiple myeloma NCCN guidelines.2024. [Cited 2024 Sep 17]. Available from:https:\/\/www.nccn.org\/home\/member\u2010"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.127"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.820768"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.209"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(96)00075-X"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10020336"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002838"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01162-7"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02614"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_433520"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010020\u20100750\u2010z"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02567"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01696"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174044"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19623"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27327"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.20050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T08:24:17Z","timestamp":1760689457000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.20050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1111\/bjh.20050"],"URL":"https:\/\/doi.org\/10.1111\/bjh.20050","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"assertion":[{"value":"2024-10-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}